Labiotech.eu

News and Trends 25 Aug 2022

Biotech stocks enjoy brief rally with uncertain winds ahead

Global biotech stocks have briefly risen after sinking steadily over the last year. Whether this recovery lasts is another question. Here are the latest biotech stock trends for 2022. In early 2021, biotech stock markets began a long period where stocks dropped in value caused by investors fleeing the sector. This season, known as a […]

August 25, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 25 Aug 2022

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […]

August 25, 2022 - 3 minutesmins - By Liza Laws

Best in Biotech 25 Aug 2022

Five cleantech companies making New Zealand more green

Cleantechs are focused on reducing negative environmental impacts by offering recycling, renewable energy, green chemistry solutions and more. From extracting gold from old electronics to seaweed supplements for cattle, here are five cleantech companies hailing from New Zealand. New Zealand has been ranked fourth in the world for biotechnology innovation potential. By leveraging the country’s […]

August 25, 2022 - 4 minutesmins - By Omnia Ibrahim

coronavirus COVID 19 Europe biotech lungs

News and Trends 25 Aug 2022

Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer

Patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases have completed their last visit in a clinical trial studying the drug, Zorifertinib. Drugs developer, Alpha Biopharma, announced the completion today (August 25) of last patient last visit (LPLV) in its international, multicenter EVEREST phase 2/3 study of the next-generation […]

August 25, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

3T Biosciences launches with $40M financing

3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Scottish researchers can tap into new £300K fund

Precision Medicine Scotland Innovation Centre (PMS-IC), the national center for accelerating the advancement and adoption of precision medicine, has launched a new fund to support Scottish researchers. The $300,000 ($355,000) fund, the first offered by PMS-IC, will support research ideas to support accurate diagnosis and/or treatment based on an individual’s unique biology. Funds of up […]

August 25, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

New drug boosts options for rheumatoid arthritis treatment

In its final phase III clinical trial, a new drug for treating rheumatoid arthritis has proved to be at least as effective as the current “gold standard” treatment for this autoimmune disease. This opens up new treatment options for affected patients. The results of the international multicentre study led by MedUni Vienna were recently published […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.

Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25) announced an investment from Takeda Ventures, Inc. (TVI), the strategic arm of Takeda. TVI investment joins Zelluna’s latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical […]

August 25, 2022 - 2 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever

A Belgian university spinoff has generated the biggest seed capital financing in the institution’s history. Closing with €30 million ($30 million), AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds

Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents. These are: one in India, and continuation patents in China, Australia and the U.S. This means the company’s method for using modified bacteria for treatment of both mucosal and cutaneous wounds in […]

August 25, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Evotec SE acquires highly-flexible drug manufacturing space for €1

A clinical and commercial manufacturing platform for small molecule therapeutics has expanded following an acquisition signed for. Evotec SE made the announcement today (August 25) after signing the contract yesterday for €1 to take Central Glass Germany GmbH from Japanese manufacturing company Central Glass Co. Ltd. It will now operate as Evotec Drug Substance (Germany) […]

August 25, 2022 - 2 minutesmins - By Liza Laws

huntingtons disease dementia prilenia therapeutics

News and Trends 24 Aug 2022

Clearance given to clinical trial with potential to change course of brain disease

A trial to look at gene therapy, BV-01, for Huntington’s Disease has been given the go ahead to take place in France and has ‘the potential to change the course of the devastating disease. Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, received clearance for the phase 1/2 […]

August 24, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biotech stocks enjoy brief rally with uncertain winds ahead

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

Five cleantech companies making New Zealand more green

Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer

3T Biosciences launches with $40M financing

Scottish researchers can tap into new £300K fund

New drug boosts options for rheumatoid arthritis treatment

Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.

KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever

Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds

Evotec SE acquires highly-flexible drug manufacturing space for €1

Clearance given to clinical trial with potential to change course of brain disease

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!